# US 2020/0286597 A1 · System for Detecting an Intraoral Disease and Determining a Personalized Treatment Scheme and Method of Doing Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0286597 A1
- Document ID: US20200286597A1
- Status: Published application
- Kind: A1
- Application number: 16/753,386
- Filed: 2018-10-04
- Published: 2020-09-10
- Earliest claimed: 2017-10-04
- Assignees: Cannibite BVBA
- Applicants: Cannibite Bvba
- Inventors: Veronica Stahl
- Web page: https://patentgrep.com/patent/US20200286597A1

## CPC

- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- A61B 10/0051: {for taking saliva or sputum samples (devices for receiving spittle A61J9/00)}
- A61K 8/368: with carboxyl groups directly bound to carbon atoms of aromatic rings
- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61K 8/9789: Magnoliopsida [dicotyledons]
- C12Q 1/18: Testing for antimicrobial activity of a material
- C12Q 1/689: for bacteria
- G16H 10/60: for patient-specific data, e.g. for electronic patient records
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- A61K 2800/92: Oral administration
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The current invention discloses a system for detecting an intraoral disease and determining a personalized treatment scheme; the system comprising: a. a reservoir configured for accommodating a sample of a biologic material collected in an oral cavity of a patient; b. a first detector for detecting a first substance originating from bacteria; c. a second detector for detecting a second substance originating from at least one of an immune and an inflammatory system of the patient; d. a control unit configured for operatively receiving signals from the first and second detectors and analyzing the signals; and e. display and communication means configured for presenting results of signal analysis; wherein the control unit is configured for determining said treatment scheme comprising relevant antimicrobial compositions and a dosing frequency thereof. Additionally, the present invention recommends customized cannabis-based oral care products.

## Claims

### Claim at position 1

1-80. (canceled)

### Claim 81

A system for providing a personalized oral care formulation for a patient, said system comprising:
a. a detection module for detecting in vitro at least one of oral bacterial, viral and/or fungal infection in a sample of oral cavity obtained from said patient;
b. an in vitro test module for testing antibacterial, antiviral and/or antifungal activity of a panel comprising antimicrobial, antiviral, antifungal compounds or combinations thereof,
the detection module and the in vitro test module being separated or combined in the same module; and
c. an oral care compounding module for receiving data from said in vitro test module concerning effectiveness of compounds comprised in said panel on at least one of antibacterial, antiviral and/or antifungal activity in said patient's sample;
wherein said oral care compounding module provides instructions on producing an oral care formulation comprising at least one antimicrobial, antiviral and/or antifungal compound comprised in said panel having a more effective antibacterial, antiviral and/or antifungal activity in vitro compared to other antimicrobial, antiviral or antifungal compounds.

### Claim 82 (depends on 81)

The system of claim 81 further comprising an oral care compound cartridge containing said oral care formulation, optionally wherein the oral care compound cartridge is configured to be operationally connected to the patient's toothpaste package, dentifrice package or mouthwash container.

### Claim 83 (depends on 81)

The system according to claim 81, wherein said oral care formulation is in the form of a mouthwash, dentifrice or toothpaste.

### Claim 84 (depends on 81)

The system according to claim 81, wherein said panel of antimicrobial, antiviral and/or antifungal compounds comprises at least one cannabinoid, and optionally further comprises at least one of chlorhexidine compounds, chlorhexidine gluconate, cationic antimicrobial compounds, essential oils, fluoride compounds, chlamoxicillin, amoxicillin/clavulanate, clindamycin, metronidazole, at least one herbal extract, optionally punica granatum extract, pomegranate extract, or any combination thereof.

### Claim 85 (depends on 81)

The system according to claim 81, wherein said oral care compounding module is operationally connected to an oral care formulation production line.

### Claim 86 (depends on 81)

The system according to claim 81, wherein said system additionally comprises a database for storing output of the patient results from the detection module, the in vitro test module or the oral care compounding module, or any combination thereof.

### Claim 87 (depends on 81)

The system according to claim 81, wherein said system additionally comprises a server configured for processing and storing the patient's medical and/or dental data.

### Claim 88 (depends on 84)

The system according to claim 84, wherein said at least one cannabinoid is at least one of cannabinoid acid derivatives, optionally Tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabinolic acid (CBNA), cannabigerolic acid (CBGA), cannabichromenic acid (CBCA), cannabinodiolic acid (CBNDA), or any combination thereof.

### Claim 89 (depends on 84)

The system according to claim 84, wherein said at least one cannabinoid is an extract of any part of a cannabis plant and/or or a cannabinoid selected from the group consisting of Dronabinol, Nabiximols, Nabilone, Tetrahydrocannabinol (THC), Cannabidiol (CBD), Levonantradol, Ajulemic acid (CT3), Δ9-tetrahydrocannabinol (ECP002A), naturally occurring Δ9-THC, Cannabichromene (CBC), Cannabichromevarin (CBCV), Cannabichromevarinic acid (CBCVA), Cannabidiol monomethylether (CBDM), Cannabidiorcol (CBD-C1), Cannabidivarin (CBDV), Cannabidivarinic acid (CBDVA), Cannabielsoin (CBE, CBL), Cannabielsoic acid B (CBEA-B), Cannabielsoin acid A (CBEA-A), Cannabigerol (CBG), Cannabigerol monomethylether (CBGM), Cannabigerolic acid monomethylether (CBGAM), Cannabigerovarin (CBGV), Cannabigerovarinic acid (CBGVA), Cannabinol (CBN), Cannabinodiol (CBND, CBDL), Cannabinodivarin (CBVD), Cannabinol methylether (CBNM), Cannabinol-C2 (CBN-C2), Cannabinol-C4 (CBN-C4), Cannabinolic acid (CBNA), Cannabiorcool (CBN-C1), Cannabivarin (CBV), Cannabitriol (CBT), 10-Ethoxy-9-hydroxy-delta-6a-tetrahydrocannabinol, 8,9-Dihydroxy-delta-6a-tetrahydrocannabinol, Cannabitriolvarin (CBTV), Delta-8-tetrahydrocannabinols, Delta-8-tetrahydrocannabinol (Δ8-THC), Delta-8-tetrahydrocannabinolic acid (Δ8-THCA), Delta-9-tetrahydrocannabinols, Delta-9-tetrahydrocannabinol (THC), Delta-9-tetrahydrocannabinol-C4 (THC-C4), Delta-9-tetrahydrocannabinolic acid A (THCA-A), Delta-9-tetrahydrocannabinolic acid B (THCA-B), Delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4), Delta-9-tetrahydrocannabiorcol (THC-C1), Delta-9-tetrahydrocannabiorcolic acid (THCA-C1), Delta-9-tetrahydrocannabivarin (THCV), Delta-9-tetrahydrocannabivarinic acid (THCVA), 10-Oxo-delta-6a-tetrahydrocannabinol (OTHC), Cannabichromanon (CBCF), Cannabifuran (CBF), Cannabiglendol, Cannabiripsol (CBR), Cannbicitran (CBT), Dehydrocannabifuran (DCBF), Delta-9-cis-tetrahydrocannabinol (cis-THC), Tryhydroxy-delta-9-tetrahydrocannabinol (triOH-THC), 3,4,5,6-Tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol, 8-OH-iso-HHCV, 9α-OH-HHC, or any combination thereof.

### Claim 90

A method for providing a patient a personalized oral care formulation, the method comprising steps of:
a. obtaining a sample from an oral cavity of said patient;
b. incubating said sample in vitro for detecting at least one of oral bacterial, viral or fungal infection;
c. in vitro testing antibacterial, antiviral and/or antifungal activity of a panel comprising at least one of antimicrobial, antiviral and/or antifungal compounds, or combination thereof, the incubating and the testing, steps, (b) and (c), being separate steps or combined in the same step; and
d. receiving data from said in vitro test concerning effectiveness of at least one compound comprised in said panel on at least one of antibacterial, antiviral, or antifungal activity in said patient's sample;
e. providing instructions on producing an oral care formulation comprising at least one antimicrobial, antiviral or antifungal compound comprised in said panel having a more effective antibacterial, antiviral and/or antifungal activity in vitro compared to other antimicrobial, antiviral or antifungal compounds; and
f. administering the oral care formulation to said patient.

### Claim 91 (depends on 90)

The method according to claim 90, wherein said oral care formulation is in the form of a mouthwash, dentifrice or toothpaste.

### Claim 92 (depends on 90)

The method according to claim 90, wherein said panel of antimicrobial, antiviral and/or antifungal compounds comprises at least one cannabinoid, and optionally further comprises at least one of chlorhexidine compounds, chlorhexidine gluconate, cationic antimicrobial compounds, essential oils, fluoride compounds, chlamoxicillin, amoxicillin/clavulanate, clindamycin, metronidazole, at least one herbal extract, optionally punica granatum extract, pomegranate extract, or any combination thereof.

### Claim 93 (depends on 90)

The method according to claim 90, wherein said method further comprises collecting and storing data of the patient, the data being medical and/or dental data.

### Claim 94 (depends on 92)

The method according to claim 92, wherein said at least one cannabinoid is at least one of cannabinoid acid derivatives, optionally THCA, CBDA, CBNA, CBGA, CBCA, CBNDA or any combination thereof.

### Claim 95 (depends on 92)

The method according to claim 92, wherein said at least one cannabinoid is an extract of any part of a cannabis plant and/or or a cannabinoid selected from the group consisting of Dronabinol, Nabiximols, Nabilone, THC, CBD, Levonantradol, CT3, ECP002A, naturally occurring Δ9-THC, CBC, CBCV, CBCVA, CBDM, CBD-C1, CBDV, CBDVA, CBE, CBL, CBEA-B, CBEA-A, CBG, CBGM, CBGAM, CBGV, CBGVA, CBN, CBND, CBDL, CBVD, CBNM, CBN-C2, CBN-C4, CBNA, CBN-C1, CBV, CBT, 10-Ethoxy-9-hydroxy-delta-6a-tetrahydrocannabinol, 8,9-Dihydroxy-delta-6a-tetrahydrocannabinol, CBTV, Delta-8-tetrahydrocannabinols, Δ8-THC, Δ8-THCA, Delta-9-tetrahydrocannabinols, Delta-9-tetrahydrocannabinol (THC), Delta-9-tetrahydrocannabinol-C4 (THC-C4), Delta-9-tetrahydrocannabinolic acid A (THCA-A), Delta-9-tetrahydrocannabinolic acid B (THCA-B), Delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4), Delta-9-tetrahydrocannabiorcol (THC-C1), Delta-9-tetrahydrocannabiorcolic acid (THCA-C1), Delta-9-tetrahydrocannabivarin (THCV), Delta-9-tetrahydrocannabivarinic acid (THCVA), OTHC, CBCF, CBF, Cannabiglendol, CBR, CBT, DCBF, Delta-9-cis-tetrahydrocannabinol (cis-THC), triOH-THC, 3,4,5,6-Tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol, 8-OH-iso-HHCV, 9α-OH-HHC, or any combination thereof.

### Claim 96

A personalized oral care formulation for a patient comprising at least one antimicrobial, antiviral, antifungal compound or a combination thereof previously tested in vitro in an oral sample from said patient and determined as being effective or having a greater antimicrobial, antiviral and/or antifungal activity compared to other antimicrobial, antiviral or antifungal compounds tested in vitro in the same oral sample of the same patient.

### Claim 97 (depends on 96)

The personalized oral care formulation according to claim 96, wherein said antimicrobial, antiviral and/or antifungal compounds comprise at least one cannabinoid, and optionally further comprises at least one of chlorhexidine compounds, chlorhexidine gluconate, cationic antimicrobial compounds, essential oils, fluoride compounds, chlamoxicillin, amoxicillin/clavulanate, clindamycin, metronidazole, at least one herbal extract, optionally punica granatum extract, pomegranate extract, or any combination thereof.

### Claim 98 (depends on 97)

The personalized oral care formulation according to claim 97, wherein said at least one cannabinoid is at least one of cannabinoid acid derivatives, optionally THCA, CBDA, CBNA, CBGA, CBCA, CBNDA, or any combination thereof.

### Claim 99 (depends on 97)

The personalized oral care formulation according to claim 97, wherein said at least one cannabinoid is an extract of any part of a cannabis plant and/or or a cannabinoid selected from the group consisting of Dronabinol, Nabiximols, Nabilone, THC, CBD, Levonantradol, CT3, ECP002A, naturally occurring Δ9-THC, CBC, CBCV, CBCVA, CBDM, CBD-C1, CBDV, CBDVA, CBE, CBL, CBEA-B, CBEA-A, CBG, CBGM, CBGAM, CBGV, CBGVA, CBN, CBND, CBDL, CBVD, CBNM, CBN-C2, CBN-C4, CBNA, CBN-C1, CBV, CBT, 10-Ethoxy-9-hydroxy-delta-6a-tetrahydrocannabinol, 8,9-Dihydroxy-delta-6a-tetrahydrocannabinol, CBTV, Delta-8-tetrahydrocannabinols, Δ8-THC, Δ8-THCA, Delta-9-tetrahydrocannabinols, Delta-9-tetrahydrocannabinol (THC), Delta-9-tetrahydrocannabinol-C4 (THC-C4), Delta-9-tetrahydrocannabinolic acid A (THCA-A), Delta-9-tetrahydrocannabinolic acid B (THCA-B), Delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4), Delta-9-tetrahydrocannabiorcol (THC-C1), Delta-9-tetrahydrocannabiorcolic acid (THCA-C1), Delta-9-tetrahydrocannabivarin (THCV), Delta-9-tetrahydrocannabivarinic acid (THCVA), OTHC, CBCF, CBF, Cannabiglendol, CBR, CBT, DCBF, Delta-9-cis-tetrahydrocannabinol (cis-THC), triOH-THC, 3,4,5,6-Tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol, 8-OH-iso-HHCV, 9α-OH-HHC, or any combination thereof.

### Claim 100 (depends on 96)

The personalized oral care formulation according to claim 96, wherein said oral care formulation is in a form of a mouthwash, dentifrice or toothpaste.
